Hello, my name is Martin, CEO of Xbrane. I have with me our CFO, Jane, and we will present the Q3 2026 report for the company. I will, as usual, go through a brief operational update related to the quarter, and Jane will thereafter go through the financial highlights. First, a snapshot of our development portfolio, starting with our biosimilar to Lucentis, which is under the brand name Ximluci on the market in Europe and select countries in the Middle East, and now recently got approved by the US FDA under the brand name Lucamzi. We have a partnership with STADA for the European market and a partnership with Valorum Biologics for future commercialization in the US. Our second product, Xdivane, is a biosimilar candidate to Opdivo, partnered with Intas and Accord Healthcare. We recently announced that the pivotal clinical pharmacokinetic trial was fully recruited. We are looking forward to the clinical readout in Q2 next year, followed by a submission of a BLA to the US FDA, and then Xdarzane, our Darzalex biosimilar candidate, which is in early stage development, partnered up with JOINN Biologics, which is conducting process development currently. In parallel to that, Xbrane is seeking commercialization partners for that product. But we'll go through this a little bit more in depth one by one and starting then with Lucamzi in the US. We are very happy, of course, with the recent FDA approval. We are now going through preparations with our partner for launch during the course of next year. And yes, a snapshot of the market. I think the right way to look at this is as anti-VEGF inhibitors for retinal disorders. That is a market of about €9 billion, with about 10 million units being administered annually across the US. So it is a very sizable market. There are about 16 products in that market as far as we can tell. Six branded or originator products, and ten biosimilars, both on Eylea and on Lucentis. So, I think for us, this poses a big opportunity. Of course, it is a very sizable market. And even if we were to capture just 1% of that market, it could reach sales of up to 100 million USD. So it's a very sizable market. And we are now, together with our partners, forming the commercial strategy for the product. So it is a little bit too early to say how this will pan out. But we can note that given the dynamics in the US market, new entrants are actually favored. In the segment of products which falls under Medicare Part B, due to the structure with reimbursement on the back, the list price before you have an average sales price established is essentially the list price minus the discounts that are given. So I think these dynamics typically favor new entrants because you are able to structure it so that it becomes economically beneficial for, in this case, the eye clinics. So we are quite optimistic that this will go well, and we will make the most out of this opportunity together with our partners. And I said what lies ahead of us. Before a launch is above all, of course, production of material. We are going through that during the remainder of this year, essentially, then preparations with our partner Valorum of course, which relates to applying for the so-called Q-code, which is required essentially for reimbursement upon administration of the product. I think this is crucial to have in place before launch. That takes six months to get in place. It is just an administrative process. So there is no risk or anything attached to that, but it is an application which needs to be processed. So therefore we should have that by mid next year, after which we believe a launch can take place. But as I said, this is really something we do now in collaboration with our partners.
And now, a few words about Europe. And then a few words about Europe. As I said, Ximluci, which is the brand name in Europe, has been on the market since 2023 across 24 countries in Europe and the Middle East, with a quite simple commercialization structure. We have co-developed the product together with STADA, and we are sharing the profit contribution. 50/50, and here is a historical graph with the profit share essentially that has gone to Xbrane over the quarters since launch in Europe. And we have an accumulated profit sharing of about 145 million Swedish kronor throughout this time period. And you can see on this graph that it varies quite a bit from quarter to quarter. And it mostly has to do with the way this is accounted for, where actually the profit sharing is recognized as revenue upon shipment of the goods to STADA and the shipment goes in cycles. So that is why there is a little bit of variation quarter by quarter. But I think if we look at this, where we stand now, it's generating about 50 million Swedish kronor a year in profit sharing for Xbrane. With that said, we have a 6% volume market share, when looking at only the Ranibizumab market. So that's a share of the total VEGF inhibitor market. We are, as we have talked about before, going through several cost reduction measures. We believe that is crucial to bring down the production cost. Given an increase in competition. And this will bear fruit in the second half of next year, essentially. And we believe then that this could unlock further growth opportunities across Europe and the Middle East. We also have a remaining inventory position of 149 million Swedish crowns, essentially mainly drug substance gradually being converted to drug product. And so, to STADA mainly, we believe that will be converted during the remainder of this year and next year, essentially to cash. So that was an overview of where we stand with regards to Lucamzi or Ximluci, and shifting gear over to Xdivane, our biosimilar candidate to Opdivo. And so this is then targeting the whole PD-1 inhibitor market. So essentially Opdivo and Keytruda. And that is about €40 billion in annual net sales. So, a massive market opportunity. And it should be noted that Opdivo goes off patent first. So that's December 2028 in the US, and the Keytruda patent lapses some six months after. But we do believe there is an opportunity for biosimilars to be there day one, post-Opdivo patent expiration, to also capture market share from Keytruda. So massive market opportunity. And we believe we are well positioned from a timeline perspective in this race towards patent expiration. From a competitive perspective, we know Amgen already submitted their BLA to the FDA, but I do believe that we are second in that group of expected biosimilars. Having fully recruited our pivotal clinical trial. And then we have three other biosimilar candidates under development and in clinical trials. So eventually, we do expect to see five or so biosimilars to Opdivo on the market. But it is really about being there in the first wave, or preferably, upon patent expiration, which we really do believe that we are going to be able to be. A partnership with Accord Healthcare in relation to this product provides us with a very strong partner for commercialization. Accord Healthcare, which is a sales subsidiary of Intas, has a very high market share in Europe when it comes to oncology injectables. It is also establishing itself in the US with its acquisition of the Coherus Pegfilgrastim biosimilar a while ago. And also, a handful of products on their way to market. We believe we have a strong commercialization partner, and we are confident that Accord Healthcare will do a fabulous job in commercializing this product. And again, from a timeline perspective, we are now going through, on the one hand, all the CMC related activities which are remaining. So that is drug substance, drug product process validation and characterization, which is going according to plan. Again, the pivotal clinical trial was fully recruited with 340 patients in melanoma, and we are going to have an interim readout in Q2 next year. And then we are planning for a submission of a BLA to the FDA mid next year. We are preparing to receive approval and be in a position to launch by the patent expiration at the end of 2028. So I think this is going very much according to plan. Currently, I am very excited about the prospects of this program. Moving forward, I think a natural question to have, and a question we often get, is why should we believe that this biosimilar candidate is going to be approved on the first attempt by the FDA, given the delays we've had with Lucamzi. And it's a fair comment, but I think it's important to look at this in a little bit more detailed manner. What held us back with Lucamzi was really related to GMP issues at contract manufacturers, and it was related to unresolved observations from inspections by the FDA. We had two CRLs due to that. As you might recall, the FDA in the first BLA we sent in did not have any comments in relation to the clinical development nor the whole analytical comparability package, which are two other important aspects of the BLA. So we've learned from this when it comes to Xdivane, and we work with one of the top ten contract manufacturers globally with two sites involved, having had successful FDA inspections since 2010 and supplying commercial product to the US since. So we do believe that we have reduced the risk in relation to potential issues with the FDA related to inspections at manufacturing sites. And I do believe there is a high probability that we are going to get approved the first time when we submit the BLA to the FDA. So we're quite excited about this program and it could be very valuable to Xbrane. We have shown this slide before, and we had Venture Valuation, an independent pharmaceutical product valuation company located in Switzerland, perform an evaluation of Xdivane essentially. And you can see on the right-hand side of this slide all the assumptions that they took in this valuation, but it's essentially just looking at the expected market or the expected sales of the originator product by the time of launch. Looking at the trajectory of other oncology biosimilars in the US when it comes to volume, market share as well as price decline and applying those curves or trends to this situation in combination with the expected competitive situation, essentially.
And then applying the relevant cost structure and profit sharing mechanism, and all that together. Their estimate was that this could generate about €100 million in profit sharing at its peak to Xbrane, which of course would be a fabulous and very sizable opportunity for us. So we're very excited about this program and what it could do for patients, of course, but also for Xbrane as a company.
Then moving on to Xdarzane, this is more early-stage, as I mentioned, but we're quite excited about this program as well. It is addressing a very sizable originator product now at about 14 billion USD, actually. And we are navigating this through without having to invest further into the program from Xbrane's perspective. So essentially, the arrangement here is that JOINN Biologics, which is a prominent biologics CDMO with sites in both the US and China, is going through process development of this biosimilar candidate, and the target is to get towards comparative analytical demonstration by mid-next year, after which we can take this program further to scale up production of clinical material and go into the clinic, and so on, in parallel.
Xbrane is seeking a commercialization partner, similar to the partnerships we have established with STADA as well as Intas in the past. We are seeking a similar structure with a partner that is interested in commercializing this biosimilar candidate once approved. So early stage, but quite interesting opportunity still. So, to summarize, the key takeaways from this quarter. Ximluci launched across 24 countries in Europe and the MENA region, generating about 50 million Swedish kronor per year in profit sharing for us now. We are going through cost reduction measures, which will bear fruit in the second half of next year and, we hope, unlock further growth opportunities. Lucamzi has received FDA approval and we are now going through preparations for launch during the course of next year, together with our partners. And then for Xdivane, the pivotal pharmacokinetic trial was fully recruited in October, and we are moving in a timely fashion toward a day one launch in the US, late 2028. And then early development will start, Xdarzane, and we are working through establishing a deal with a commercialization partner. So these are the key takeaways from an operational perspective of the quarter.
And I therefore hand over to Jane to go through the financial highlights.